Diagnostic Medical Systems: directors' dealings · France · AMF

About Diagnostic Medical Systems

DIAGNOSTIC MEDICAL SYSTEMS, now communicated under the DMS Group / DMS Imaging brand, is a French industrial company specializing in the design, development and manufacture of high-performance medical imaging systems. Listed on Euronext Growth Paris under ISIN FR0012202497 and ticker ALDMS, the company focuses on two core markets: digital radiology and bone densitometry. Its main production site is located in Gallargues-le-Montueux in southern France, giving the group a solid industrial footprint in France while supporting a broad international commercial reach. DMS’ business model is built around two main product families. The first is digital radiology, where the company develops imaging systems for hospitals, radiology practices and imaging networks, including fixed radiography rooms, mobile radiology platforms and complementary diagnostic solutions. The second is bone densitometry, a segment in which DMS positions itself as a European reference. Its Medix and Stratos ranges are designed and manufactured in France and are supported by software and clinical tools intended to improve workflow efficiency and diagnostic accuracy. The company also highlights advanced features such as 3D-DXA, a technology that enhances bone analysis and body composition assessment. From a market standpoint, DMS is a mid-cap industrial player with strong export exposure. The group states that it serves customers across all continents through a network of more than 140 national distributors, and that 75% of 2024 revenue came from outside France. That international footprint is a key part of its growth strategy. Financially, DMS reported €46.1 million of revenue in 2024, then €50.0 million in 2025, representing 9% organic growth. The company also posted €10 million of revenue in Q1 2026, confirming continued operating momentum. A number of recent milestones reinforce the company’s strategic profile. In 2025, DMS secured FDA clearance for its !M1 mobile radiology system in the United States as part of its partnership with JPI Healthcare Solutions, marking a significant step in its North American expansion. The group also emphasizes its Imaging 2027 strategic plan, which aims to deliver profitable, sustainable growth through innovation, industrial execution and broader international penetration. Another notable feature is DMS’ niche leadership in Europe’s bone densitometry market, where it describes itself as the only European manufacturer in a field otherwise dominated by U.S. and South Korean competitors.